du Plessis Willem J, Keyser Alana, Walzl Gerhard, Loxton André G
SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000 South Africa.
Clinical Laboratory Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
J Inflamm (Lond). 2016 Jul 29;13:23. doi: 10.1186/s12950-016-0133-4. eCollection 2016.
Mycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life. The role of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector cells in addition to their role as antibody producing cells during disease. Here we aim to identify and characterize the frequency of peripheral B-cell subpopulations during active Tuberculosis and over treatment response. Analysis were done for both class switched (CS) and non-class switched (NCS) phenotypes.
We recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy community controls. All groups were followed up for one week from recruitment and the TB cases till the end of treatment (month 6).
Peripheral blood samples were collected, stained with monoclonal antibodies to CD19(+) cells, Immunoglobulin (Ig) M, plasma cells (CD 138(+)), marker of memory (CD27(+)), immune activation (CD23(+)) and acquired on a flow cytometer. Circulating Marginal zone B cells (CD19(+)IgM(+)CD23(-)CD27(+)) and memory phenotypes are able to distinguish between TB diagnosis and end of treatment. The frequency of mature B cells from TB cases are lower than that of other-lung diseases at diagnosis. A subpopulation of activated memory B cells (CD19(+)IgM(+)CD23(+)CD27(+)) cells are present at the end of TB treatment.
This study identified distinctive B cell subpopulations present during active TB disease and other lung disease conditions. These cell populations warrants further examination in larger studies as it may be informative as cell markers or as effectors/regulators in TB disease or TB treatment response.
结核分枝杆菌(Mtb)仍然是一个尚未解决的威胁,每年导致大量生命损失。B细胞在针对Mtb的保护性免疫中的作用仍不清楚。除了在疾病期间作为抗体产生细胞的作用外,B细胞还被描述为效应细胞。在这里,我们旨在识别和表征活动性结核病期间外周B细胞亚群的频率以及治疗反应。对类别转换(CS)和非类别转换(NCS)表型均进行了分析。
我们招募了未经治疗的活动性肺结核患者、其他肺部疾病患者和健康社区对照。所有组从招募开始随访一周,结核病病例随访至治疗结束(第6个月)。
采集外周血样本,用针对CD19(+)细胞、免疫球蛋白(Ig)M、浆细胞(CD138(+))、记忆标志物(CD27(+))、免疫激活(CD23(+))的单克隆抗体进行染色,并在流式细胞仪上进行检测。循环边缘区B细胞(CD19(+)IgM(+)CD23(-)CD27(+))和记忆表型能够区分结核病诊断和治疗结束。结核病病例中成熟B细胞的频率在诊断时低于其他肺部疾病。在结核病治疗结束时存在一个活化记忆B细胞亚群(CD19(+)IgM(+)CD23(+)CD27(+))。
本研究识别出了活动性结核病和其他肺部疾病状态下存在的独特B细胞亚群。这些细胞群体值得在更大规模的研究中进一步检查,因为它们可能作为结核病疾病或结核病治疗反应中的细胞标志物或效应器/调节因子提供信息。